Skip To Main Content
Elisabetta Metafuni on Muck Rack

Elisabetta Metafuni

As seen in: Nature, Wiley Online Library, Frontiers, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Elisabetta

Contact Elisabetta, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Early deterioration and subsequent recovery of nursing complexity after CAR-T therapy: a prospective score-based analysis

|
By Eugenio Galli, Ilaria Pansini, Alessandro Corrente, Fabio M. Lamberti, Marco Cioce, Elisabetta Metafuni, Sabrina Giammarco, Federica Sorà, Patrizia Chiusolo, Simona Sica, Elisabetta Schifitto, Pasquale Rea, Giorgia Brizzi, Alessio Capitani, Teresa Laviano, Cinzia Sechi
| Nature Verified
Dear Editor, Chimeric antigen receptor T-cell (CAR-T) therapy has significantly improved outcomes in relapsed or refractory B-cell hematologic malignancies, although it is associated with a unique toxicity profile—including cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), cytopenias, infections, and metabolic instability—requiring intensive monitoring and specialized nursing care [1].
Open in Who Shared Issue with article?

Lymphodepletion and donor lymphocyte infusions (LD-DLI) for DLI-non responsive myelofibrosis

|
By Patrizia Chiusolo, Andrea Bacigalupo, Luca Castagna, Sabrina Giammarco, Federica Sorà, Elisabetta Metafuni, Maria Assunta Limongiello, Eugenio Galli, Filippo Frioni, Simona Sica
| Nature Verified
The treatment of choice for patients with myelofibrosis (MF), relapsing after an allogeneic stem cell transplantation (HSCT), is the infusion of donor lymphocytes (DLI) in escalating doses [1]. This procedure is particularly effective when patients are treated at the time of molecular relapse (MRel) [2]. For patients not responding to DLI, the current European Group for Blood and Marrow Transplantation (EBMT) guidelines, suggest a second allogeneic HSCT [3].
Open in Who Shared Issue with article?

Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT

|
By Simone Cesaro, Chiara Garonzi, Gloria Tridello, Inge Verheggen, Daihong Liu, Catherine Flynn, Ali Alahmari, Leylagül Kaynar, Werner Rabitsch, Vedat Uygun, Pedro Chorão, Jiong Hu, Albert Esquirol, José Luis Piñana, Mahmoud Aljurf, Eva Wagner-Drouet, Peter Lang, Guillermo Martín-Sánchez, Barbara Nasilowska-Adamska, Jan Styczynski, Ron Ram, Elisabetta Metafuni, Alina Doina Tanase, Krzysztof Kalwak, Bianca Serio, Hasan Hashem, Luca Castagna, Marta González Vicent, Musa Karakukcu, Ioannis Baltadakis, Edoardo Benedetti, Malgorzata Mikulska, Rafael de la Camara, Dina Averbuch, Siret Ratip, Luca Facchini, Khaled Halahleh
| Nature Verified
Hemorrhagic cystitis (HC) is a frequent complication after hematopoietic cell transplant (HCT), with an incidence ranging from 2 to 66% depending on the type of transplant and the age of the patient [1,2]. In the last two decades, the use of post-transplant cyclophosphamide (PT-Cy) as graft-versus-host-disease (GVHD) prophylaxis has been associated with an increased incidence of HC [3,4].
Open in Who Shared Issue with article?
See all 14 articles